[GRAND RAPIDS, Mich., Dec. 12, 2023] – BAMF Health, a global leader in Theranostics is excited to announce a major victory at the AutoPET II challenge at MICCAI 2023 (Medical Image Computing and Computer Assisted Intervention International Conference.) BAMF Health was awarded top honors in both competition categories for Accurate Detection and Segmentation of FDG-Avid Tumor Lesions (i.e. Highly Accurate Cancer Detection) and Robust Behavior Under Varying Acquisition Protocols and Sites (i.e. Consistent Performance Across Different Settings). These honors highlight the versatility and strength of the global artificial intelligence team and platform at BAMF Health.
The AutoPET Challenge is a prestigious contest in medical technology, focusing on a type of medical scanning called PET/CT, which is crucial for identifying various forms of cancer. Positron Emission Tomography/Computed Tomography, or PET/CT, uses radioactive molecules, called tracers, that accumulate in specific areas of the body and create light as the radioactive atoms break down. The most common PET tracer is a radioactive form of sugar called Fludeoxyglucose or FDG. These advanced FDG-PET PET/CT scans allow doctors to examine how different parts of the body are using sugar, which may indicate the presence of cancer. The AutoPET Challenge encourages the development of new computer-based methods for automatically identifying cancer signs in these PET/CT scans.
“The future of patient outcomes lies within our willingness to embrace technological advancement,” said Dr. Stephen Moore, VP of Artificial Intelligence at BAMF Health. “Our submission to the MICCAI conference this year proves BAMF Health’s ability to harness the transformative potential of AI, ensuring a healthcare landscape that is not just responsive, but anticipatory. BAMF is paving the way for human expertise and machine intelligence to become a powerful force for healing and progress.”
At the conference this year, BAMF Health stood out for two main achievements:
- Highly Accurate Cancer Detection: BAMF Health’s technology accurately identifyed cancer signs in the PET/CT scans, carefully distinguishing them from unaffected parts of the body that also absorb sugar, like the brain, kidneys, and heart. The team showed exceptional proficiency in error avoidance while ensuring the meticulous detection of any potential indicators of cancer pathology.
- Consistent Performance Across Different Settings: BAMF Health’s system proved to be reliable even when the PET/CT scans were taken under slightly different conditions or in various hospitals, showing that their approach is versatile and dependable.
“We’re so proud of our team’s work in the AutoPET II Challenge. Winning in both categories demonstrates the effectiveness and versatility of the technology we’ve built in the complex domain of molecular imaging and medical scanning,” said Dr. Gowtham Murugesan, Senior Deep Learning Engineer at BAMF Health. “By integrating AI into patient diagnostics and therapeutics, BAMF Health’s comprehensive precision medicine platform yields affordable and accessible medicine for our patients that need us most.”
BAMF Health reaffirms their promise is to improve cancer diagnosis using the most advanced technology available; winning the AutoPET II Challenge reaffirms their role as a global leader in creating precise and flexible tools for cancer detection in PET/CT scans.
If you or someone you know has experienced a cancer diagnosis, BAMF Health can help. Visit www.bamfhealth.com/patients to learn more about their cancer diagnostic capabilities.
About BAMF Health: BAMF Health has created the world’s first vertically integrated platform for Intelligence Based Precision Medicine through AI-enabled Molecular Imaging and Theranostics. Our approach focuses on intelligence-based treatment. Our state-of-the-art platform allows us to see what we treat – and treat what we see. We help patients spend less time in the hospital, feel better faster, and simply get back to living their life.
